GT Biopharma Inc. (GTBP) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

GT Biopharma Inc. (GTBP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.36

-0.16 (-6.35%)

At close: Jan 15, 2025, 3:59 PM

2.30

-2.54%

After-hours Jan 15, 2025, 06:41 PM EST

undefined% (undefined)

Bid	2.29
Market Cap	5.27M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-7.39
PE Ratio (ttm)	-0.32
Forward PE	n/a
Analyst	Buy

Ask	2.32
Volume	90,951
Avg. Volume (20D)	453,647
Open	2.46
Previous Close	2.52
Day's Range	2.36 - 2.63
52-Week Range	1.72 - 10.66
Beta	undefined

About GTBP

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 27, 2018

Employees 2

Stock Exchange NASDAQ

Ticker Symbol GTBP

Website https://www.gtbiopharma.com

Analyst Forecast

According to 1 analyst ratings, the average rating for GTBP stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 366.10% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 weeks ago · Source

+60.57%

GT Biopharma shares are trading higher. Roth MKM i... Unlock content with Pro Subscription

7 months ago · Source

-28.21%

GT Biopharma shares are trading lower after the company announced a $3.2 million registered direct offering of 740,000 shares of common stock at $4.35 per share.

News

8 months ago · invezz.com

What made GT Biopharma stock more than double on Monday?

GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn't been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company.

8 months ago · investorplace.com

Why Is GT Biopharma (GTBP) Stock Up 143% Today?

GT Biopharma (NASDAQ: GTBP ) stock is soaring higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 10.6 million shares of GT...

1 year ago · zacks.com

GT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

1 year ago · zacks.com

Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now

1 year ago · zacks.com

All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy

GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 years ago · seekingalpha.com

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

3 years ago · zacks.com

OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade

OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).